Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1115-1121 , August 2010

Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

Received 2 July 2009 ,Accepted 19 February 2010.

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. New Engl J Med. 2004;351:1860–1873
  2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  3. Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–952
  4. Tosi P, Zamagni E, Ronconi S, et al. Safety of autologous haematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia. 2000;14:1310–1313
  5. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–829
  6. Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006;134:385–390
  7. Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dyalisis-dependent renal failure. Haematologica. 2006;91:1555–1558
  8. Knudsen LM, Nielsen B, Gimsing P, et al. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27–33
  9. Parikh G, Amjad AI, Saliba RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:812–816
  10. Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35:985–990
  11. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med. 1990;150:1693–1695
  12. Bladé J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–1893
  13. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–39
  14. Rajkumar SV, Blood E, Vesole D, et al. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  15. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98–103
  16. Eriksson T, Bjorkman S, Hoglund T. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001;57:365–376
  17. Eriksson T, Hoglund P, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol. 2003;55:1701–1706
  18. Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122:160–161
  19. Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol. 2004;125:96–97
  20. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826–831
  21. Zamagni E, Valdre L, Palareti G, et al. Prevention of VTE in multiple myeloma patients. Thromb Res. 2007;120(Suppl 2):S133–S136
  22. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  23. Zamagni E, Testoni N, Terragna C, et al. Incorporation of thelidomide into up-front double autologous stem cell transplntation (ASCT) for multiple myeloma improves the outcome in comparison with double ASCT without thalidomide: analysis of baseline factors predictive of outcome. Blood. 2007;110;[abstract]
  24. Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997;20:211–217
  25. Desikan RK, Jagannath S. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Semin Oncol. 2001;28:593–596
  26. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007;21:1294–1299
  27. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–2042
  28. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal insufficiency in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–549
  29. Cavo M, Patriarca F, Tacchetti P, et al. Bortezomib (Velcade®)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood. 2007;110:73
  30. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood. 2008;112:158;[abstract]
  31. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606
  32. Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411–1414
  33. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;28:906–917
  34. Dimopoulos MA, Richardson P, Schlag R, et al. Bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients with impaired renal function: cohort analysis of the phase III VISTA study. Blood. 2008;112:1727;[abstract]
  35. Dimopoulos MA, Roussou M, Kastritis E, et al. Reversibility of renal impairment of multiple myeloma patients treated with bortezomib-based regimens: identification of predictive factors. Blood. 2008;112:1725;[abstract]
  36. San Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842–849
  37. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol. 2007;153:87–104
  38. Sengul S, Zwizinski C, Simon EE, et al. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 2002;62:1977–1988
  39. Sarközi R, Perco P, Hochegger K, et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther. 2008;327:645–656
  40. Herrera GA, Russell WJ, Isaac J, et al. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol. 1999;23:107–126
  41. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy?. Haematologica. 2007;92:1302–1307

 Financial disclosure: See Acknowledgments on page 1120.

PII: S1083-8791(10)00093-5

doi: 10.1016/j.bbmt.2010.02.020

Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1115-1121 , August 2010

Article Tools

* Image Usage & Resolution